000 06005nam a22006255i 4500
001 978-3-031-20537-8
003 DE-He213
005 20240207153557.0
007 cr nn 008mamaa
008 230410s2023 sz | s |||| 0|eng d
020 _a9783031205378
_9978-3-031-20537-8
050 4 _aRS199.5
072 7 _aTCB
_2bicssc
072 7 _aSCI010000
_2bisacsh
072 7 _aTCB
_2thema
082 0 4 _a615.6
_223
245 1 0 _aViral Drug Delivery Systems
_h[electronic resource] :
_bAdvances in Treatment of Infectious Diseases /
_cedited by Ranjita Shegokar, Yashwant Pathak.
250 _a1st ed. 2023.
264 1 _aCham :
_bSpringer International Publishing :
_bImprint: Springer,
_c2023.
300 _aX, 409 p. 53 illus., 47 illus. in color.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
500 _aAcceso multiusuario
505 0 _aGlobal health and Viral diseases past, present and Future -- Drug resistance and statistics and patent status -- cellular understanding viral diseases -- Viral: current treatment options -- Mucosal drug delivery strategies for antiviral intervention -- Micro, nano emulsions in viral -- Novel formulation approaches to treat Ebola- virus -- Ebola- drug delivery -- Polymers for Bio sensing Applications in antiviral therapy and diagnosis -- Nanotechnology: A Stepping Stone towards Viral Hepatitis Treatment and Prevention in Children -- Recent Developments in the Treatment of Influenza -- Covid 19: from molecular pathogenesis to potential repurposed treatments -- Nano drug delivery systems for Covid-19-drug delivery -- Exploring the link between malaria and Covid 19 -- Characterization of biofunctionalized nanoparticles in ID -- Covid- azithromycin-ritonavir -- Strategies to combat Covid-19 drug delivery -- Phytomolecules and NDDS Covid-19.
520 _aThe disability-adjusted life year (DALY) is a generic measure of health effect that can be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year (QALY). Infectious diseases are one of the major to cause significant losses of DALY and QALY. Human infectious diseases are disorders that are triggered by the micro-organisms such as bacteria, fungi, viruses, or parasites. The majority of such diseases are contagious and create a public health menace. There are several reasons why infectious diseases are deadly diseases, and one of the primary reasons is the drug resistance developed over time. Drug resistance-associated mutations are linked to increasing drug efflux, modifications of the drugs, or their targets. Every year, new drugs are being approved by FDA to treat infectious diseases. Nonetheless, the infectious diseases will undoubtedly persist as permanent and main threats to humanity for now and in the future, primarily due to increased longevity that almost always comes at a cost of impaired immunity. A total of four books are covered under the series of Infectious drug diseases. - Malarial drug delivery systems - Tubercular drug delivery systems - Viral drug delivery systems - Infectious disease drug delivery systems The third volume of series is focused on viral drug delivery systems. Typically, virus attaches to the cells (referred as host cell) and releases its DNA or RNA inside the cell. In second stage, virus's genetic material takes control of the cell and forces it to replicate the virus leading to onset of disease symptoms. DNA class of viruses include Herpes, Papilloma and Adeno viruses. RNA class of viruses include retroviruses, such as HIV immunodeficiency virus and SARS COV - 2 / Corona virus. This book addresses recent developments in viral drug delivery systems. It covers many different aspects of viral infections, ways to treat them using modern drug delivery systems like nano particulate carriers. The choice of viral delivery systems mainly depends upon the type of virus, duration of life cycle, presence of drug resistance, cellular and mucosal interaction of virus, accordingly gene or non-gene drug delivery systems are selected. Besides that, this book also reports global dynamics of viral diseases, future predictions of infection rate, current treatment options, details of drug carriers like nanoemulsions, polymeric nanoparticles, role of biofunctionalization, and phyto-molecules in treatment of viral infections particularly herpes, Covid-19, Ebola, HIV/AIDS, influenza and viral hepatitis. Audiences from a broad range of groups, from researchers, academicians, and public health bodies to regulatory experts, can benefit from the compiled information to learn more about patient needs and current research advances in the field of viral drug delivery research.
541 _fUABC ;
_cPerpetuidad
650 0 _aDrug delivery systems.
650 0 _aPharmaceutical chemistry.
650 0 _aDiseases.
650 0 _aPharmacology.
650 0 _aEpidemiology.
650 0 _aPharmacy.
650 1 4 _aDrug Delivery.
650 2 4 _aPharmaceutics.
650 2 4 _aDiseases.
650 2 4 _aPharmacology.
650 2 4 _aEpidemiology.
650 2 4 _aPharmacy.
700 1 _aShegokar, Ranjita.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aPathak, Yashwant.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
773 0 _tSpringer Nature eBook
776 0 8 _iPrinted edition:
_z9783031205361
776 0 8 _iPrinted edition:
_z9783031205385
776 0 8 _iPrinted edition:
_z9783031205392
856 4 0 _zLibro electrónico
_uhttp://libcon.rec.uabc.mx:2048/login?url=https://doi.org/10.1007/978-3-031-20537-8
912 _aZDB-2-SBL
912 _aZDB-2-SXB
942 _cLIBRO_ELEC
999 _c261512
_d261511